

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
16 May 2019 (16.05.2019)(10) International Publication Number
WO 2019/094533 A8

(51) International Patent Classification:

C07K 16/26 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2018/059734

(22) International Filing Date:

08 November 2018 (08.11.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/584,637 10 November 2017 (10.11.2017) US

(71) Applicant: **NGM BIOPHARMACEUTICALS, INC.**
[US/US]; 333 Oyster Point Blvd., South San Francisco, CA
94080 (US).(72) Inventors: **CHU, Chun**; 333 Oyster Point Boulevard,
South San Francisco, CA 94080 (US). **DING, Xunshan**;
1360 Millbrae Ave., Millbrae, CA 94030 (US). **LIU,**
Zhonghao; 333 Oyster Point Boulevard, South San Fran-
cisco, CA 94080 (US). **WANG, Yan**; 333 Oyster Point
Boulevard, South San Francisco, CA 94080 (US). **YIN,****Yiyuan**; 5220 Fairbanks Common, Fremont, CA 94555
(US). **ZHAI, Wenwu**; 602 Teredo Drive, Redwood City,
CA 94065 (US).(74) Agent: **KOIPALLY, Joseph J.** et al.; Fish & Richardson
P.C., P.O. Box 1022, Minneapolis, Minnesota 55440-1022
(US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: ANGPTL8-BINDING AGENTS AND METHODS OF USE THEREOF

FIG. 1A

Heavy chain variable region sequence alignments

Kabat	1	10	22	31--35	40	50--a-----60---65
AbM	1	10	22	26-----35	40	50--a-----58
Chothia	1	10	22	26---32	40	a-55
Contact	1	10	22	30---35	40	47-----a-----58
IMGT	1	23	27-----38	41	56-----65	74
AHon	1	23	27	42	57	76

1E5	QVQLQQSGAELVKPGTSTVRLSCKAS	GYTFDYYTH	WVKLRSGQGLEWIG	WFYPGSDNIKYNKFKD
1E9	QVQLQQSGTELKPGASVKLSCKAS	GYTFDYYTH	WVKQRSQGLEWIG	WFYPGSDNIKFNKFRD
1A8	QVQLQQSGAELVKPGASVKLSCKAS	GYTFDYYTH	WVKQRSQGLEWIG	WFYPGSDNIKYNKFKD
Consensus		GYTFDYYTH		WFYPGSDNIKXKFXD
		(SEQ ID NO:11)		(SEQ ID NO:58)

Kabat	70	80	abc	90	95-----102	110
AbM	70	80	abc	90	95-----102	110
Chothia	70	80	abc	90	96-----101	110
Contact	70	80	abc	90	93-----101	110
IMGT	75	89			105-----117	
AHon				109	138	

1E5	KATLTADKSSSTVYMDLRLTSEDSAVYFCAR	HEAFSYVDVAFW	WGQGLTVTVSA	(SEQ ID NO:35)
1E9	KATLTADKSSSTVYMLSRITSEDSAVYFCAR	HEAFVYVDVAFW	WGQGLTVTVST	(SEQ ID NO:44)
1A8	KATLTADKSSSIVYMELSRITSEDSAVYFCAR	HEAAYVYDVAFW	WGQGLTVTVSA	(SEQ ID NO:56)
Consensus		HEAXXXYDVAFW		
		(SEQ ID NO:59)		

(57) Abstract: The present disclosure provides binding agents, such as antibodies, that specifically bind angiopoietin-like protein 8 (ANGPTL8), including human ANGPTL8, and methods of their use.

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:

16 April 2020 (16.04.2020)

(15) Information about Correction:

see Notice of 16 April 2020 (16.04.2020)